1. **WELCOME AND APOLOGIES**

The Chair welcomed the participants, including the new external expert Dr Simonnard. Two apologies were announced by the Chair.

Dr Varvaresou, newly appointed SCCS external expert, has resigned for professional reasons and lack of time due to her new responsibilities in her Institution.

2. **ADOPTION OF THE AGENDA**

The agenda was adopted as it was presented.

3. **DECLARATION OF INTEREST ON MATTERS ON THE AGENDA**

The Chair invited participants to declare any interest regarding matters on the agenda. None of the participants declared any interest conflicting with the matters on the agenda.

4. **NEW MANDATE**

The new mandate on 2-(4-tert-buty benzyl)propionaldehyde (BMHCA) CAS 80-54-6 Submission II is planned to be adopted and the rapporteur to be appointed at the next plenary meeting (6 June).

5. **OPINIONS**

- **Aluminium – Submission II:** the draft opinion was discussed and tasks among members allocated to progress in the development of the Opinion. A revised version is planned to be added on the agenda of the next plenary meeting (6 June) for further discussion.

- **HEMA 2-hydroxyethyl methacrylate (CAS 868-77-9, EC 212-782-2), and Di-HEMA Trimethylhexyl Dicarbamate (CAS 41137-60-4/72869-86-4, EC -/276-957-5):** the draft opinion was discussed and tasks among members allocated to progress in the development of the Opinion. All references of the dossier are still missing and have
been requested to the applicant. A revised version could be added on the agenda of the next plenary meeting (6 June), for further discussion, should all references be provided.

- **SKIN SENSITISATION QUANTITATIVE RISK ASSESSMENT METHOD (QRA 2):** The draft opinion was discussed and tasks among members allocated to progress in the development of the Opinion. A revised version is planned to be added on the agenda of the next plenary meeting (6 June) for further discussion.

- **FRAGRANCE VETIVER OIL- SUBMISSION III:** The draft opinion was discussed and tasks among members allocated to progress in the development of the Opinion. A request for clarification to the applicant is under drafting.

- **FRAGRANCE 2-(4-tert-butylbenzyl)propionaldehyde (BMHCA):** Tasks among members were allocated to start developing the Opinion. A draft version of the opinion is planned to be added on the agenda of the next plenary meeting (6 June) for discussion.

6. **COMMENTS RECEIVED ON OPINIONS ADOPTED**

**VITAMIN A – SCCS/1576/16**

The clarification request received was discussed and the SCCS response agreed on. It will be added on the agenda of the next plenary meeting (6 June) for information.

7. **INFORMATION FROM CHAIRMAN/MEMBERS/COMMISSION**

SCCS Vice-Chair, Vera Rogiers, participated in the BfR/RIVM workshop on validation and regulatory acceptance of alternative methods held on 23-24 March 2017:

Most alternative methods are not stand-alone tests and cannot on their own replace the *in vivo* test. Therefore, different methods are combined in so-called testing strategies or integrated approaches. Until now, no official procedure exists to evaluate the driving parameters mentioned for a testing strategy, which could inhibit its regulatory acceptance. For this reason different stakeholders were invited to discuss the topic and try to come to some expert recommendations. An official report is planned to be produced jointly by the organising BfR and RIVM. This report might be useful for SCCS discussion on methodologies and the future revision of its Notes of Guidance.

8. **ANY OTHER BUSINESS**

Next meetings:

30 June 2017, 30 August and 27 September 2017.